Cellectis Moves First Off-The-Shelf CAR-T Into US Clinical Trials

UCART123 is behind the initial wave of CAR-T drugs for cancer but could have a big advantage as an allogeneic, or off-the-shelf, option. A Phase I trial is now under way in patients with acute myeloid leukemia.

Cellectis SA has taken a pivotal step in moving forward a potential first allogeneic, or "off-the-shelf," chimeric antigen receptor T-cell (CAR-T) therapy with the initiation of a clinical trial in the US. The company announced the first patient has been dosed in a Phase I clinical study testing the investigational product, UCART123, in patients with acute myeloid leukemia June 27.

Coinciding with the news, Cellectis announced June 28 the appointment of two experienced pharma executives as directors, Rainer Boehm and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immuno-oncology

More from Anticancer